Morgan Stanley Analysts Give Novartis (VTX:NOVN) a CHF 84 Price Target

Morgan Stanley set a CHF 84 price objective on Novartis (VTX:NOVN) in a research note published on Monday, Borsen Zeitung reports. The brokerage currently has a sell rating on the stock.

A number of other brokerages have also weighed in on NOVN. Deutsche Bank set a CHF 90 target price on shares of Novartis and gave the company a neutral rating in a research report on Monday, September 16th. Bank of America set a CHF 104 target price on shares of Novartis and gave the company a buy rating in a research report on Friday, September 13th. JPMorgan Chase & Co. set a CHF 82 target price on shares of Novartis and gave the company a sell rating in a research report on Thursday, October 17th. Credit Suisse Group set a CHF 88 target price on shares of Novartis and gave the company a neutral rating in a research report on Friday, July 19th. Finally, UBS Group set a CHF 88 target price on shares of Novartis and gave the company a neutral rating in a research report on Friday, October 18th. Three research analysts have rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the company. The stock currently has a consensus rating of Hold and an average target price of CHF 90.73.

Novartis has a one year low of CHF 72.45 and a one year high of CHF 88.30.

Novartis Company Profile

Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum.

Featured Article: How to track put option volume

Analyst Recommendations for Novartis (VTX:NOVN)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.